A Meta-Analysis of GBA-Related Clinical Symptoms in Parkinson’s Disease by Yuan Zhang, Li Shu, Xun Zhou, Hongxu Pan, Qian Xu, Jifeng Guo, Beisha Tang, Qiying Sun

Get full text

Identification of Cognitive Training for Individuals with Parkinson’s Disease: A Systematic Review by Marina Francesca Gattoni, Silvia Gobbo, Sarah Feroldi, Anna Salvatore, Jorge Navarro, Sandro Sorbi, Francesca Lea Saibene

“…<b>Background/Objectives</b>: Parkinson’s disease (PD) is a neurodegenerative disorder, characterised by cardinal motor features and a multitude of non-motor manifestations. …”
Get full text

Rapid Screening for Cognitive Impairment in Parkinson’s Disease: A Pilot Study by YanHong Dong, Way Inn Koay, Leonard Leong Litt Yeo, Christopher Li-Hsian Chen, Jing Xu, Raymond Chee Seong Seet, Erle Chuen Hian Lim

Get full text

Clinical Factors Predicting Voluntary Driving Cessation among Patients with Parkinson’s Disease by Hidetada Yamada, Masahiro Nakamori, Tomohisa Nezu, Teppei Kotozaki, Juri Kitamura, Tomohiko Ohshita, Yoshimasa Sueda, Hirofumi Maruyama

“…Factors that influence the decision of voluntary driving cessation in patients living with Parkinson’s disease (PD) are still unclear. We aimed to reveal the factors affecting the decision of voluntary driving cessation in patients with PD. …”
Get full text

Central Aortic Pressure and Arterial Stiffness in Parkinson’s Disease: A Comparative Study by Mehmet Balal, Meltem Demirkiran, Saime Paydas

“…Cardiovascular autonomic dysfunction, which leads to hemodynamic disorders, is commonly observed in patients with Parkinson’s disease (PD). Central aortic pressure (CAP) is the systolic blood pressure (SBP) at the root of the aorta. …”
Get full text

Correlation of MRI Visual Scales with Neuropsychological Profile in Mild Cognitive Impairment of Parkinson’s Disease by Luiz Felipe Vasconcellos, João Santos Pereira, Marcelo Adachi, Denise Greca, Manuela Cruz, Ana Lara Malak, Helenice Charchat-Fichman, Mariana Spitz

“…Few studies have evaluated magnetic resonance imaging (MRI) visual scales in Parkinson’s disease-Mild Cognitive Impairment (PD-MCI). …”
Get full text

Cortical Lewy Body Dementia by W. R. G. Gibb

“…In cortical Lewy body dementia the distribution of Lewy bodies in the nervous system follows that of Parkinson's disease, except for their greater profusion in the cerebral cortex. …”
Get full text

Efficacy of Moxibustion in the Treatment of Parkinson’s Disease Based on Meta-Analysis under Intelligent Medical Treatment by Qianqian Niu, Weijie Xu

“…Dementia in Parkinson’s disease (PD) has become a major factor affecting the quality of life of patients with Parkinson’s disease. …”
Get full text

Generation and characterization of two induced pluripotent stem cell lines (ICGi052-A and ICGi052-B) from a patient with frontotemporal dementia with parkinsonism-17 associated wit... by E. V. Grigor’eva, A. A. Malakhova, E. S. Yarkova, J. M. Minina, Y. V. Vyatkin, J. A. Nadtochy, E. A. Khabarova, J. A. Rzaev, S. P. Medvedev, S. M. Zakian

“…Frontotemporal dementia with parkinsonism-17 is a neurodegenerative disease characterised by pathological aggregation of the tau protein with the formation of neurofibrillary tangles and subsequent neuronal death. …”
Get full text

Consensus on the Definition of Advanced Parkinson’s Disease: A Neurologists-Based Delphi Study (CEPA Study) by Maria-Rosario Luquin, Jaime Kulisevsky, Pablo Martinez-Martin, Pablo Mir, Eduardo S. Tolosa

“…To date, no consensus exists on the key factors for diagnosing advanced Parkinson disease (APD). To obtain consensus on the definition of APD, we performed a prospective, multicenter, Spanish nationwide, 3-round Delphi study (CEPA study). …”
Get full text

A network-based systems genetics framework identifies pathobiology and drug repurposing in Parkinson’s disease by Lijun Dou, Zhenxing Xu, Jielin Xu, Chengxi Zang, Chang Su, Andrew A. Pieper, James B. Leverenz, Fei Wang, Xiongwei Zhu, Jeffrey Cummings, Feixiong Cheng

“…Abstract Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder. …”
Get full text

Sicca Symptoms in Parkinson’s Disease: Association with Other Nonmotor Symptoms and Health-Related Quality of Life by Tino Prell, Denise Schaller, Caroline Perner, Otto W. Witte, Julian Grosskreutz

“…Autonomic symptoms (Survey of Autonomic Symptoms, SASs), motor function (Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale III, MDS-UPDRS III), nonmotor symptoms (nonmotor symptoms questionnaire, NMS-Quest), and QoL (PD Questionnaire-39, PDQ-39) were analysed in 93 PD patients without dementia. …”
Get full text

Predicting Cognitive Decline in Parkinson’s Disease with Mild Cognitive Impairment: A One-Year Observational Study by Pei-Hao Chen, Fang-Yu Cheng, Shih-Jung Cheng, Jin-Siang Shaw

“…We conducted an observational study to investigate clinical predictors of cognitive decline in patients with mild cognitive impairment (MCI), with a focus on patients with Parkinson’s disease (PD) and Alzheimer’s disease (AD). …”
Get full text

Psychosis as an Isolated Manifestation of COVID-19 in Non-Demented Patients with Parkinson's Disease: Clinical Cases and Literature Review by G. Lokominaitė, R. Kaladytė Lokominienė

“…Despite the recognition of cognitive deficit as a major risk factor for psychosis in Parkinson's disease, psychotic events have been reported in patients without dementia. …”
Get full text

Improvement of Blood Plasmalogens and Clinical Symptoms in Parkinson’s Disease by Oral Administration of Ether Phospholipids: A Preliminary Report by Shiro Mawatari, Shinji Ohara, Yoshihide Taniwaki, Yoshio Tsuboi, Toru Maruyama, Takehiko Fujino

“…Introduction. Parkinson’s disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease (AD). …”
Get full text

Subthalamic Nucleus Deep Brain Stimulation in Early Stage Parkinson’s Disease Is Not Associated with Increased Body Mass Index by Sarah H. Millan, Mallory L. Hacker, Maxim Turchan, Anna L. Molinari, Amanda D. Currie, David Charles

“…Previous studies suggest that deep brain stimulation of the subthalamic nucleus (STN-DBS) for Parkinson’s disease (PD) leads to weight gain. This study analyzes changes in body mass index (BMI) in 29 subjects from a prospective, single-blind trial of DBS in early stage PD (age 50–75, Hoehn & Yahr stage II off medication, treated with antiparkinsonian medications for ≥6 months but <4 years, and without a history of motor fluctuations, dyskinesias, or dementia). …”
Get full text

Evidence for alpha-synuclein aggregation in older individuals with hyposmia: a cross-sectional studyResearch in context by Kenneth Marek, David S. Russell, Luis Concha-Marambio, Seung Ho Choi, Danna Jennings, Michael C. Brumm, Christopher S. Coffey, Ethan Brown, John Seibyl, Matthew Stern, Claudio Soto, Andrew Siderowf

“…Summary: Background: Synuclein pathology in neurodegenerative diseases, such as Parkinson’s disease (PD) and Dementia with Lewy bodies (DLB), begins years before motor or cognitive symptoms arise. …”
Get full text

Addenbrooke’s Cognitive Examination and Individual Domain Cut-Off Scores for Discriminating between Different Cognitive Subtypes of Parkinson’s Disease by Dagmar Berankova, Eva Janousova, Martina Mrackova, Ilona Eliasova, Milena Kostalova, Svetlana Skutilova, Irena Rektorova

“…The main aim of this study was to verify the sensitivity and specificity of Addenbrooke’s Cognitive Examination-Revised (ACE-R) in discriminating between Parkinson’s disease (PD) with normal cognition (PD-NC) and PD with mild cognitive impairment (PD-MCI) and between PD-MCI and PD with dementia (PD-D). …”
Get full text

Dementia after DBS Surgery: A Case Report and Literature Review by I. Rektorova, Z. Hummelova, M. Balaz

“…We report the case history of a 75-year-old woman with Parkinson's disease who developed severe cognitive problems after deep brain stimulation (DBS) of the bilateral subthalamic nuclei (STN). …”
Get full text

Multi-functional role of apolipoprotein E in neurodegenerative diseases by Sadequl Islam, Arshad Noorani, Yang Sun, Makoto Michikawa, Kun Zou

“…It also covers ApoE’s influence in other neurodegenerative diseases like Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration (FTLD), Huntington’s disease (HD), vascular dementia (VD), and multiple sclerosis (MS). …”
Get full text